Learn the pathophysiology of atherosclerotic vascular disease, explore non-statin lipid-lowering therapies, and gain insights into managing hyperlipidemia in statin-intolerant patients to reduce cardiovascular risk.
Cardiovascular disease (CVD) remains the leading cause of death in the U.S. despite public health initiatives. Hyperlipidemia is a major risk factor for developing CVD, and strong clinical evidence supports the use of statin therapy to reduce the risk of cardiovascular events. However, statin therapy is not always feasible for all patients due to contraindications and adverse events. Statin intolerance occurs in 5-20% of patients, particularly older adults. Thus, healthcare professionals need to learn about non-statin lipid-lowering agents to provide alternative therapeutic pathways for patients with statin intolerance.
This course will delve into the pathophysiology of atherosclerotic vascular diseases and identify biological targets for drug intervention. It will also cover various non-statin treatment options, their clinical applications, and potential adverse effects, providing healthcare professionals with comprehensive insights into managing hyperlipidemia and reducing cardiovascular risk.
Online MembershipSave up to 70% by coming a memberParticipants must correctly enter the 4-digit evaluation access code provided into the test at the conclusion of the webinar and complete an activity evaluation. Credits will be reported automatically to CPE Monitor and/or CE Broker if your license information is entered properly in your profile and if the course is completed on the same day of the webinar. If you fail to complete the attendance confirmation on the same day, please contact AchieveCE’s customer support to ensure your credits are reported.
Discount code: